Effects of Cannabidiol on Burnout Syndrome and Empathy of Caregivers of Older Adults
Launched by UNIVERSITY OF SAO PAULO · Sep 25, 2024
Trial Information
Current as of June 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of cannabidiol, a compound found in cannabis, on burnout syndrome and empathy in caregivers who look after older adults. Burnout can lead to physical and emotional exhaustion, impacting both the caregiver's health and the quality of care they provide. The study aims to see if cannabidiol can help reduce burnout symptoms and increase empathy among these caregivers, which is important for their well-being and the care they offer to older adults who need assistance with daily activities.
To be eligible for this study, caregivers must be between 65 and 74 years old and have certain levels of burnout and empathy as measured by specific questionnaires. Participants will be randomly assigned to receive either cannabidiol or a placebo (a non-active treatment) for four weeks. Throughout the trial, they will fill out questionnaires to track their burnout levels, empathy, and any side effects they might experience. This research is crucial for understanding how to better support caregivers in their challenging roles.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Total score 4 in the IEAVD
- • Score on the emotional exhaustion subscale of MBI 9 and/or depersonalization 6 and/or; professional achievement 10
- • Low level of empathy in the EMRI scale (i.e., total score 71)
- • In addition, they should have a score of 10 on the PHQ-9, indicating absence of expressive depressive symptoms
- Exclusion Criteria:
- • Not have the availability to participate in this phase of the research will be excluded
- • Who have ceased to exercise the position of carer of a person aged 60 years or more
- • Who no longer perform minimum workload of six hours daily and
- • Not complete the protocol of the intervention received.
About University Of Sao Paulo
The University of São Paulo (USP) is a prestigious public research university located in Brazil, renowned for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USP leverages its extensive academic resources, interdisciplinary expertise, and state-of-the-art facilities to facilitate groundbreaking research aimed at improving patient outcomes and addressing critical health challenges. The university's strong emphasis on ethical standards and regulatory compliance ensures that all clinical trials are conducted with the highest integrity, fostering collaboration among researchers, healthcare professionals, and the broader community to enhance scientific discovery and translate findings into practical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ribeirão Preto, São Paulo, Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported